Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Prokarium and Probiomed to Take Aim at ‘Montezuma’s Revenge’

By Prokarium; Probiomed | January 5, 2017

Prokarium and Probiomed collaborate in thermostable vaccine manufacture.

Prokarium and Probiomed announced the start of their collaboration to scale-up the manufacture of orally administered vaccines in a formulation that would enable stability at 40°C for several weeks. The first vaccine to be manufactured will be developed to prevent so-called ‘Montezuma’s revenge’ or diarrhea, which affects the local population as well travelers in Mexico and many countries.

The leading bacterial causes of diarrhea are Shigella, enterotoxigenic E. coli (ETEC) and Non-Typhoidal Salmonellosis which together account for 1 billion cases worldwide every year. When children in developing countries contract diarrhea and it is not treated, it can cause severe dehydration and death. A vaccine could prevent bacterial diarrhea but none is currently available.

The two-year project builds on preclinical work already conducted on a diarrhea vaccine using U.K.-based Prokarium’s novel oral vaccine delivery platform and combines this with Mexican Probiomed’s pharmaceutical manufacturing capability to construct, test and manufacture to clinical scale a novel oral, thermostable vaccine against diarrhea.

Self-administered oral vaccines will significantly reduce the cost and increase the scope of vaccination, especially if they are thermostable over several weeks during the final stages of distribution. Syringe reuse causes an estimated 1.3 million deaths and results in over $535 million in additional healthcare costs. Injections must be carried out by healthcare professionals and in combination with the need for a refrigerated supply chain, this means many people never get vaccinated.

A capsule or liquid is swallowed and passes through the stomach to the intestine where it releases safe bacteria. These have been engineered to produce vaccine from inside the body’s own immune cells — right where it is needed and where it minimizes chances of side effects.

“Prokarium’s technology avoids the need for injections with a needle and more importantly means it can be delivered to people living in remote resource-poor areas, as the vaccine is stable at high temperatures and can be manufactured for approximately one third of the price of conventional injectable vaccines.,” Ted Fjallman, Prokarium’s CEO, commented. “Together with Probiomed we now aim to prove we can scale-up and make enough of these vaccines to really make a difference to people worldwide.”

Probiomed’s CEO Jaime Uribe Wiechers added: “One of Probiomed’s strategic goals focuses on the company’s capitalization of its advanced manufacturing technologies; a very important step is taken by this collaboration. I’m positive that the technological background of this product, along with Prokarium’s expertise in biotechonolgy and our own, will lead to a high added value vaccine that will enhance people’s health on both continents.”

The collaboration is supported by the U.K. government’s Newton Fund, administered by Innovate U.K., and by the Mexican government’s innovation agency CONACYT. The project is important both for Mexico’s own people and for its tourism industry. The results will be widely applicable to many different vaccines for difficult-to-target diseases worldwide.

(Sources: Sciad Newswire)


Filed Under: Drug Discovery

 

Related Articles Read More >

Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE